drugset / Trial / NCT03005639
ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
NaSingle-groupOpen-labelTreatment
Summary
Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma • To evaluate the overall radiological complete response rate in patients with stage IIIB/C melanoma after 8 weeks of neoadjuvant vemurafenib and cobimetinib
Timeline
- Start
- 2017-06-01
- Primary completion
- 2018-02-24
- Completion
- 2018-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 20 mg | — |
| Subject | Vemurafenib | Small molecule | 240 mg | — |